Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children26010.24287/1726-1708-2019-18-3-46-53ORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИCombined treatment of diffuse sclerosing osteomyelitis of mandible in childrenКомбинированное лечение диффузно-склерозирующего остеомиелита нижней челюсти у детейhttps://orcid.org/0000-0002-6881-7709KugushevA. Yu.КугушевА. Ю.
Russian Federation

Kugushev Alexander Yurevich, PhD, plastic surgeon, pediatric surgeon, Department of Maxillofacial Surgery

119571, Moscow, Leninsky Prospekt, 117

Кугушев Александр Юрьевич, кандидат медицинских наук, врач – пластический хирург, детский хирург отделения челюстнолицевой хирургии 

119571, Москва, Ленинский пр-кт, 117

drkugushev@gmail.comhttps://orcid.org/0000-0003-0043-9059LopatinA. V.ЛопатинА. В.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0003-0319-3103YasonovS. A.ЯсоновС. А.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-8612-8851SinitsynD. S.СиницынД. С.
Russian Federation

Moscow

Москва

Russian Children's Clinical Hospital of the Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian FederationРоссийской детской клинической больницы ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииRussian Children's Clinical Hospital of the Pirogov Russian National Research Medical University of the Ministry of Healthcare of the Russian FederationРоссийская детская клиническая больница ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРeoples' friendship University of RussiaФГАОУ ВО «Российский университет дружбы народов»1309201918346531209201912092019Copyright ©; 2019, «D. Rogachev NMRCPHOI»Copyright ©; 2019, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2019«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/260

Diffuse sclerosing osteomyelitis of the jaw (DSO) is a rare and poorly understood disease. Nowadays treatment protocols (steroid or painkillers, corticotomy) do not capable of to get good and stabile results or are associated with the development of potentially serious side effects. The treatment algorithm developed by us, including the course treatment with bisphosphonates, was well tolerated and capable of to get clinical and radiological remission in the case of previous decortication and antibacterial therapy was done. For these reasons, this treatment protocol is not without interest and need of further investigates. The study was approved by the Local Ethics Committee of Russian Children's Clinical Hospital.

Диффузный склерозирующий остеомиелит нижней челюсти (ДСО) – редкое и плохо изученное заболевание. Текущие протоколы лечения (стероидные или обезболивающие препараты, кортикотомия) не позволяют достичь хороших результатов или связаны с развитием потенциально серьезных побочных эффектов. Разработанный нами алгоритм лечения, включающий курсовую терапию бисфосфонатами, хорошо переносился и позволил достичь стойкой клинико-рентгенологической ремиссии в случае проведения предшествующей декортикации и антибактериальной терапии. Данный подход к лечению ДСО перспективен и требует дальнейшего исследования. Данное исследование поддержано Локальным этическим комитетом Российской детской клинической больницы.

diffuse sclerosing osteomyelitisbisphosphonatesдиффузно-склерозирующий остеомиелитбисфосфонаты1. Montonen M., Kalso E., Pylkkaren L., Lindstrorm B.M., Lindqvist C. Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible. Int J Oral Maxillofac Surg 2001; 30 (4): 313–7.Montonen M., Kalso E., Pylkkaren L., Lindstrorm B.M., Lindqvist C. Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible. Int J Oral Maxillofac Surg 2001; 30 (4): 313–7.2. Yoshii T., Nishimura H., Yoshikawa T., Furudoi S., Yoshioka A., Takenono I., et al. Therapeutic possibilities of long-term roxithromycin treatment for chronic diffuse sclerosing osteomyelitis of the mandible. J Antimicrob Chemother 2001; 47 (5): 631–7.Yoshii T., Nishimura H., Yoshikawa T., Furudoi S., Yoshioka A., Takenono I., et al. Therapeutic possibilities of long-term roxithromycin treatment for chronic diffuse sclerosing osteomyelitis of the mandible. J Antimicrob Chemother 2001; 47 (5): 631–7.3. Jacobsson S., Hollender L. Treatment and prognosis of diffuse sclerosing osteomyelitis (DSO) of the mandible. Oral Surg Oral Med Oral Pathol 1980; 49 (1): 7–14.Jacobsson S., Hollender L. Treatment and prognosis of diffuse sclerosing osteomyelitis (DSO) of the mandible. Oral Surg Oral Med Oral Pathol 1980; 49 (1): 7–14.4. van Merkesteyn J.P., Groot R.H., Bras J., Bakker D.J. Diffuse sclerosing osteomyelitis of the mandible: clinical radiographic and histologic findings in twenty-seven patients. J Oral Maxillofac Sur 1988; 46 (10): 825–9.van Merkesteyn J.P., Groot R.H., Bras J., Bakker D.J. Diffuse sclerosing osteomyelitis of the mandible: clinical radiographic and histologic findings in twenty-seven patients. J Oral Maxillofac Sur 1988; 46 (10): 825–9.5. Montonen M., Iizuka T., Hallikainen D., Lindqvist C. Decortication in the treatment of diffuse sclerosing osteomyelitis of the mandible. Retrospective analysis of 41cases between 1969 and 1990. Oral Surg Oral Med Oral Pathol 1993; 75 (1): 5–11.Montonen M., Iizuka T., Hallikainen D., Lindqvist C. Decortication in the treatment of diffuse sclerosing osteomyelitis of the mandible. Retrospective analysis of 41cases between 1969 and 1990. Oral Surg Oral Med Oral Pathol 1993; 75 (1): 5–11.6. Suei Y., Tanimoto K., Miyauchi M., Ishikawa T. Partial resection of the mandible for the treatment of diffuse sclerosing osteomyelitis: report of four cases. J Oral Maxillofac Surg 1997; 55 (4): 410–5.Suei Y., Tanimoto K., Miyauchi M., Ishikawa T. Partial resection of the mandible for the treatment of diffuse sclerosing osteomyelitis: report of four cases. J Oral Maxillofac Surg 1997; 55 (4): 410–5.7. Mari A., Morla A., Melero M., Schiavone R., Rodriguez J. Diffuse sclerosing osteomyelitis (DSO) of the mandible in SAPHO syndrome: a novel approach with antiTNF therapy. Systematic review. J Cranio-Maxillo-Facial Surg 2014; 42: 1990–6.Mari A., Morla A., Melero M., Schiavone R., Rodriguez J. Diffuse sclerosing osteomyelitis (DSO) of the mandible in SAPHO syndrome: a novel approach with antiTNF therapy. Systematic review. J Cranio-Maxillo-Facial Surg 2014; 42: 1990–6.8. Groot R.H., van Merkesteyn J.P., van Soest J.J., Bras J. Diffuse sclerosing osteomyelitis (chronic tendoperiostitis) of the mandible. An 11-year follow-up report. Oral Surg Oral Med Oral Pathol 1992; 74 (5): 557–60.Groot R.H., van Merkesteyn J.P., van Soest J.J., Bras J. Diffuse sclerosing osteomyelitis (chronic tendoperiostitis) of the mandible. An 11-year follow-up report. Oral Surg Oral Med Oral Pathol 1992; 74 (5): 557–60.9. Kuijpers S.C., de Jong E., Hamdy N.A., van Merkesteyn J.P. Initial results of the treatment of diffuse sclerosing osteomyelitis of the mandible with bisphosphonates. J Craniomaxillofac Surg 2011; 39 (1): 65–8.Kuijpers S.C., de Jong E., Hamdy N.A., van Merkesteyn J.P. Initial results of the treatment of diffuse sclerosing osteomyelitis of the mandible with bisphosphonates. J Craniomaxillofac Surg 2011; 39 (1): 65–8.10. Soubrier M., Dubost J.J., Ristori J.M., Sauvezie B., Bussiere J.L. Pamidronate in the treatment of diffuse sclerosing osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92 (6): 637–40.Soubrier M., Dubost J.J., Ristori J.M., Sauvezie B., Bussiere J.L. Pamidronate in the treatment of diffuse sclerosing osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92 (6): 637–40.11. Sugata T., Fujita Y., Myoken Y., Kiriyama T. Successful management of severe facial pain in patients with diffuse sclerosing osteomyelitis (DSO) of the mandible using disodium clodronate. Int J Oral Maxillofac Surg 2003; 32 (5): 574–5.Sugata T., Fujita Y., Myoken Y., Kiriyama T. Successful management of severe facial pain in patients with diffuse sclerosing osteomyelitis (DSO) of the mandible using disodium clodronate. Int J Oral Maxillofac Surg 2003; 32 (5): 574–5.12. Hino S., Murase R., Terakado N., Shintani S., Hamakawa H. Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy. Int J Oral Maxillofac Surg 2005; 34 (5): 576–8.Hino S., Murase R., Terakado N., Shintani S., Hamakawa H. Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy. Int J Oral Maxillofac Surg 2005; 34 (5): 576–8.13. Compeyrot-Lacassagne S., Rosenberg A.M., Babyn P., Laxer R.M. Pamidronate treatment of chronic noninfectious inflammatory lesions of the mandible in children. J Rheumatol 2007; 34 (7): 1585–9.Compeyrot-Lacassagne S., Rosenberg A.M., Babyn P., Laxer R.M. Pamidronate treatment of chronic noninfectious inflammatory lesions of the mandible in children. J Rheumatol 2007; 34 (7): 1585–9.14. Yamazaki Y., Satoh C., Ishikawa M., Notani K., Nomura K., Kitagawa Y. Remarkable response of juvenile diffuse sclerosing osteomyelitis of mandible to pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104 (1): 67–71.Yamazaki Y., Satoh C., Ishikawa M., Notani K., Nomura K., Kitagawa Y. Remarkable response of juvenile diffuse sclerosing osteomyelitis of mandible to pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104 (1): 67–71.15. Otto S., Troeltzsch M., Burian E., Mahaini S., Probst F., Pautke C., et al. Ibandronate treatment of diffuse sclerosing osteomyelitis of the mandible: Pain relief and insight into pathogenesis. J Craniomaxillofac Surg 2015 Nov; 43 (9): 1837–42. DOI: 10.1016/j.jcms.2015.08.028. Epub 2015 Sep 6.Otto S., Troeltzsch M., Burian E., Mahaini S., Probst F., Pautke C., et al. Ibandronate treatment of diffuse sclerosing osteomyelitis of the mandible: Pain relief and insight into pathogenesis. J Craniomaxillofac Surg 2015 Nov; 43 (9): 1837–42. DOI: 10.1016/j.jcms.2015.08.028. Epub 2015 Sep 6.16. Kugushev A.Yu., Lopatin A.V., Yasonov S.A. Ten years of experience of alendronate treatment of craniomaxillofacial fbrous dysplasia. Pediatric hematology/oncology and immunopathology 2018; 17 (3): 36‒42. DOI: 10.24287/1726-1708-2018-17-3-36-42Kugushev A.Yu., Lopatin A.V., Yasonov S.A. Ten years of experience of alendronate treatment of craniomaxillofacial fbrous dysplasia. Pediatric hematology/oncology and immunopathology 2018; 17 (3): 36‒42. DOI: 10.24287/1726-1708-2018-17-3-36-4217. Unal E., Abaci A., Bober E, Büyükgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab 2006 Apr; 19 (4): 523–8.Unal E., Abaci A., Bober E, Büyükgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab 2006 Apr; 19 (4): 523–8.18. Ward L.M., Denker A.E., Porras A., Shugarts S., Kline W., Travers R., et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 2005 Jul; 90 (7): 4051–6. Epub 2005 Apr 12.Ward L.M., Denker A.E., Porras A., Shugarts S., Kline W., Travers R., et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 2005 Jul; 90 (7): 4051–6. Epub 2005 Apr 12.19. Bachrach L.K., Ward L.M. Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009; 94 (2): 400–9.Bachrach L.K., Ward L.M. Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009; 94 (2): 400–9.20. Ana Luiza A.A., Ivani N.S. Oral alendronate treatment for severe polyostotic fbrous dysplasia due to McCune-Albright syndrome in a child. A case report International Journal of Pediatric Endocrinology 2010; Аrticle ID 432060: 1–4.Ana Luiza A.A., Ivani N.S. Oral alendronate treatment for severe polyostotic fbrous dysplasia due to McCune-Albright syndrome in a child. A case report International Journal of Pediatric Endocrinology 2010; Аrticle ID 432060: 1–4.21. Kwon T.G. Risk factors of medication-related osteonecrosis of the jaw. In: Otto S (ed.), Medication-related osteonecrosis of the jaw, 1st ed. Berlin Heidelberg: Springer, 2014; 2743.Kwon T.G. Risk factors of medication-related osteonecrosis of the jaw. In: Otto S (ed.), Medication-related osteonecrosis of the jaw, 1st ed. Berlin Heidelberg: Springer, 2014; 2743.22. Otto S., Kwon T.G., Assaf A.T. Definition, clinical features and staging of medication-related osteonecrosis of the jaw. In: Otto S (ed.), Medication-related osteonecrosis of the jaw, 1st ed. Berlin Heidelberg: Springer, 2014; 4355.Otto S., Kwon T.G., Assaf A.T. Definition, clinical features and staging of medication-related osteonecrosis of the jaw. In: Otto S (ed.), Medication-related osteonecrosis of the jaw, 1st ed. Berlin Heidelberg: Springer, 2014; 4355.23. Then C., Horauf N., Otto S., Pautke C., von Tresckow E., Rohnisch T., et al. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. Onkologie 2012; 35 (11): 658–64.Then C., Horauf N., Otto S., Pautke C., von Tresckow E., Rohnisch T., et al. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. Onkologie 2012; 35 (11): 658–64.24. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulis I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005: 23 (34): 8580–7.Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulis I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005: 23 (34): 8580–7.25. Abu-Id M.H., Acil Y., Gottschalk J., Kreusch T. Bisphosphonate-associated osteonecrosis of the jaw. Mund-, Kiefer und Gesichtschirurgie 2006; 10 (2): 73–81.Abu-Id M.H., Acil Y., Gottschalk J., Kreusch T. Bisphosphonate-associated osteonecrosis of the jaw. Mund-, Kiefer und Gesichtschirurgie 2006; 10 (2): 73–81.26. Hoff A.O., Toth B.B., Altdundag K., Johnson M.M., Warneke C.L., Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaws in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23 (6): 826–36.Hoff A.O., Toth B.B., Altdundag K., Johnson M.M., Warneke C.L., Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaws in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23 (6): 826–36.27. Otto S., Schreyer C., Hafner S., Mast G., Ehrenfeld M., Sturzenbaum S., et al. Bisphosphonate-related osteo-necrosis of the jaws- characteristics, clinical features, localization and impact on oncological treatment. J Cranio-Maxillo-Facial Surg 2012; 40 (4): 303–9.Otto S., Schreyer C., Hafner S., Mast G., Ehrenfeld M., Sturzenbaum S., et al. Bisphosphonate-related osteo-necrosis of the jaws- characteristics, clinical features, localization and impact on oncological treatment. J Cranio-Maxillo-Facial Surg 2012; 40 (4): 303–9.28. Bartl L., von Tresckow E. Pharmacological aspects of antiresorptive drugs: bispho-sphonates and denosumab. In: Otto S (ed.), Medication-related osteonecrosis of the jaw, 1st ed. Berlin Heidelberg: Springer, 2014; 117.Bartl L., von Tresckow E. Pharmacological aspects of antiresorptive drugs: bispho-sphonates and denosumab. In: Otto S (ed.), Medication-related osteonecrosis of the jaw, 1st ed. Berlin Heidelberg: Springer, 2014; 117.29. Barret J., Worth E., Bauss F., Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clincal Pharmacol 2004; 44 (9): 951–65.Barret J., Worth E., Bauss F., Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clincal Pharmacol 2004; 44 (9): 951–65.30. Choi A., Gang H., Whang J., Gwak H. Pharmacokinetic characteristics of formulated alendronate transdermal delivery systems in rats and humans. Drug Deliv 2010 May; 17 (4): 249–54. DOI: 10.3109/10717541003680999Choi A., Gang H., Whang J., Gwak H. Pharmacokinetic characteristics of formulated alendronate transdermal delivery systems in rats and humans. Drug Deliv 2010 May; 17 (4): 249–54. DOI: 10.3109/1071754100368099931. El-Mofty S. Chronic diffuse sclerosing osteomyelitis. Oral Surg Oral Med Oral Pathol 1973; 36 (6): 898–904.El-Mofty S. Chronic diffuse sclerosing osteomyelitis. Oral Surg Oral Med Oral Pathol 1973; 36 (6): 898–904.32. Jacobsson S. Diffuse sclerosing osteomyelitis of the mandible. Int J Oral Surg 1984; 13 (5): 363–85.Jacobsson S. Diffuse sclerosing osteomyelitis of the mandible. Int J Oral Surg 1984; 13 (5): 363–85.33. Jacobsson S., Dahlen G., Moller A.J. Bacertiologic and serologic investigation in diffuse sclerosing osteomyelitis (DSO) of the mandible. Oral Surg Oral Med Oral Pathol 1982; 54 (5): 506–12.Jacobsson S., Dahlen G., Moller A.J. Bacertiologic and serologic investigation in diffuse sclerosing osteomyelitis (DSO) of the mandible. Oral Surg Oral Med Oral Pathol 1982; 54 (5): 506–12.34. van Merkesteyn J.P., Groot R.H., Bras J., McCarroll R.S., Bakker D.J. Diffuse sclerosing osteomyelitis of the mandible: a new concept of its etiology. Oral Surg Oral Med Oral Pathol 1990; 70 (4): 414–9.van Merkesteyn J.P., Groot R.H., Bras J., McCarroll R.S., Bakker D.J. Diffuse sclerosing osteomyelitis of the mandible: a new concept of its etiology. Oral Surg Oral Med Oral Pathol 1990; 70 (4): 414–9.35. van Merkesteyn J.P., Bakker D.J., van der Waal I., Kusen G.J., Egyedi P., van den Akker H.P., et al: Hyperbaric oxygen treatment of chronic osteomyelitis of the jaws. Int jOral Surg 1984; 13 (5): 386–95.van Merkesteyn J.P., Bakker D.J., van der Waal I., Kusen G.J., Egyedi P., van den Akker H.P., et al: Hyperbaric oxygen treatment of chronic osteomyelitis of the jaws. Int jOral Surg 1984; 13 (5): 386–95.36. Urade M., Noguchi K., Takaoka K., Moridera K., Kishimoto H. Diffuse sclerosing osteomyelitis of the mandible successfully treated with pamidronate: a long-term follow-up report. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114 (4): e9–e12.Urade M., Noguchi K., Takaoka K., Moridera K., Kishimoto H. Diffuse sclerosing osteomyelitis of the mandible successfully treated with pamidronate: a long-term follow-up report. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114 (4): e9–e12.37. Kahn M.F., Hayem G., Hayem F., Grossin M. Is diffuse sclerosing osteomyelitis of the mandible part of the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome? Analysis of seven cases. Oral Surg Oral Med Oral Pathol 1994; 78 (5): 594–8.Kahn M.F., Hayem G., Hayem F., Grossin M. Is diffuse sclerosing osteomyelitis of the mandible part of the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome? Analysis of seven cases. Oral Surg Oral Med Oral Pathol 1994; 78 (5): 594–8.38. Montonen M., Li T.F., Lukinmaa P.L., Sakai E., Hukkanen M., Sukura A., et al. RANKL and cathepsin K in diffuse sclerosing osteomyelitis of the mandible. J Oral Pathol Med 2006; 35 (10): 620–5.Montonen M., Li T.F., Lukinmaa P.L., Sakai E., Hukkanen M., Sukura A., et al. RANKL and cathepsin K in diffuse sclerosing osteomyelitis of the mandible. J Oral Pathol Med 2006; 35 (10): 620–5.39. Armstrong D.J., Wright S.A., Coward S.M., Finch M.B. Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronate. Ann Rheum Diss 2006; 65 (7): 976–7.Armstrong D.J., Wright S.A., Coward S.M., Finch M.B. Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronate. Ann Rheum Diss 2006; 65 (7): 976–7.40. Mantyh P. Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain 2013; 154 (Suppl. 1): S54–S62.Mantyh P. Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain 2013; 154 (Suppl. 1): S54–S62.41. Otto S., Hafner S., Mast G., Tischer T., Volkmer E., Schieker M., et al. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg 2010; 68 (5): 1158–61.Otto S., Hafner S., Mast G., Tischer T., Volkmer E., Schieker M., et al. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg 2010; 68 (5): 1158–61.42. Otto S., Pautke C., Opelz C., Westphal I., Schwager J., Bauss F., et al. Osteonecrosis of the jaw: effect of bispho-sphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 2010; 68 (11): 2837–45. Otto S., Pautke C., Opelz C., Westphal I., Schwager J., Bauss F., et al. Osteonecrosis of the jaw: effect of bispho-sphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 2010; 68 (11): 2837–45.